My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
RES-2022-168
>
Meetings
>
2022
>
09. September
>
2022-09-06 10:00 AM - Commissioners' Agenda
>
RES-2022-168
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
9/13/2022 11:54:56 AM
Creation date
9/13/2022 11:53:49 AM
Metadata
Fields
Template:
Meeting
Date
9/6/2022
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Fully Executed Version
Supplemental fields
Item
Request to Approve a Resolution Authorizing the Chair's Signature on a Opioid Litigation Allocation Agreement
Order
3
Placement
Consent Agenda
Row ID
93293
Type
Agreement
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
107
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
5. Offer enhanced family supports and home-based wrap-around services to persons with <br />OUD and any co-occurring SUD/MH conditions, co-usage, andlor co-addiction, <br />including but not limited to parent skills training. <br />6. Support for Children's Services - Fund additional positions and services, including <br />supportive housing and other residential services, relating to children being removed <br />from the home andlor placed in foster care due to custodial opioid use. <br />PART TWO: PREVENTION <br />F. PREVENT OVER.PRESCRIBING AND ENSURE APPROPRIATE <br />PRESCRIBING AND DISPENSING OF OPIOIDS <br />Support efforts to prevent over-prescribing and ensure appropriate prescribing and dispensing <br />of opioids through evidence-based, evidence-informed, or promising programs or strategies <br />that may include, but are not limited to, the following: <br />1 Training for health care providers regarding safe and responsible opioid prescribing, <br />dosing, and tapering patients off opioids. <br />2. Academic counter-detailing to educate prescribers on appropriate opioid prescribing. <br />3. Continuing Medical Education (CME) on appropriate prescribing of opioids <br />4. Support for non-opioid pain treatment alternatives, including training providers to <br />offer or refer to multi-modal, evidence-informed treatment of pain. <br />5. Support enhancements or improvements to Prescription Drug Monitoring Programs <br />(PDMPs), including but not limited to improvements that: <br />a. Increase the number of prescribers using PDMPs; <br />b. Improve point-of-care decision-making by increasing the quantity, quality, or <br />format of data available to prescribers using PDMPs or by improving the <br />interface that prescribers use to access PDMP data, or both; or <br />c. Enable states to use PDMP data in support of surveillance or intervention <br />strategies, including MAT referrals and follow-up for individuals identified <br />within PDMP data as likely to experience OUD. <br />6. Development and implementation of a national PDMP - Fund development of a <br />multistate/national PDMP that permits information sharing while providing <br />appropriate safeguards on sharing of private health information, including but not <br />limited to: <br />a. Integration of PDMP data with electronic health records, overdose episodes, <br />and decision support tools for health care providers relating to OUD. <br />7
The URL can be used to link to this page
Your browser does not support the video tag.